Owings Mills, Maryland Clinical Trials

A listing of Owings Mills, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 82 clinical trials
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free Survival (EFS) in: participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors express …

oxaliplatin
chemotherapy regimen
ebrt
pembrolizumab
esophageal carcinoma
Greater Baltimore Medical Center ( Site 0031)
 (9.3 away) Contact site
  • 32 views
  • 29 Jul, 2021
  • +147 other locations
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL Mixed Phenotype Acute Leukemia and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab …

cns leukemia
flow cytometry
chemotherapy regimen
pegaspargase
leukemia
Sinai Hospital of Baltimore
 (7.8 away) Contact site
  • 42 views
  • 31 Jul, 2021
  • +113 other locations
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability …

flow cytometry
pegaspargase
prednisone
leukemia
monoclonal antibodies
Sinai Hospital of Baltimore
 (7.7 away) Contact site
  • 84 views
  • 02 Aug, 2021
  • +118 other locations
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming …

mastectomy
aromatase inhibitor
sentinel lymph node biopsy
core needle biopsy
metastasis
Greater Baltimore Medical Center
 (9.3 away) Contact site
  • 591 views
  • 25 Jul, 2021
  • +318 other locations
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance …

cancer chemotherapy
alveolar rhabdomyosarcoma
platelet count
irinotecan
actinomycin
Sinai Hospital of Baltimore
 (7.7 away) Contact site
  • 292 views
  • 01 Aug, 2021
  • +290 other locations
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking …

isotretinoin
high-risk neuroblastoma
melphalan
carboplatin
busulfan
Sinai Hospital of Baltimore
 (7.7 away) Contact site
  • 66 views
  • 31 Jul, 2021
  • +103 other locations
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.

Chesapeake Urology Research Associates
 (9.3 away) Contact site
  • 498 views
  • 31 Jul, 2021
  • +487 other locations
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.

cancer chemotherapy
carboplatin
lung carcinoma
paclitaxel
gemcitabine
Research Site
 (9.3 away) Contact site
  • 251 views
  • 31 Jul, 2021
  • +318 other locations
Study to Evaluate the Efficacy Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.

alpha blocker
cancer
vibegron
nocturia
micturition chart
Chesapeake Urology Research Associates
 (9.3 away) Contact site
  • 959 views
  • 15 Jul, 2021
  • +170 other locations
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.

scid
major depressive disorder
Sage Investigational Site
 (9.3 away) Contact site
  • 2391 views
  • 15 Jul, 2021
  • +82 other locations